Determination of Residues and Safety Analysis of Metal Impurities in Platinum-based Antitumor Drugs

查看全文 作　　者：PENG [1]Juan;PU [1,2]Shaoping;LI [3]Guangli;HE [1]Jian;ZHANG [1]Zhirong;LIAO [1]Yunxing

机构地区：[1]Guiyan Phamaceuitical Co,Ltd.,Kunming 650106,China;[2]Kunming University of Science and Technology,Kunming 650093,China;[3]Sino-Platinum Metals Co.Ltd.,Kunming 650106,China

出　　处：《贵金属》索引2012年第33卷第A01期,共5页

基　　金：The national SME technology innovation fund(11C26215305898);Kunming SME technology innovation fund(CJ2011040) 摘　　要：The residual metal impurities in cisplatin, carboplatin and oxaliplatin were determined by ICP-AES. The samples were ignited and dissolved with HCl:HNO 3 (3:1). The method is simple and accurate. By the determination of the metal residues in the samples, the calculated actual daily exposure and concentration of the metal Pd, Ir, Rh, Ru, Mo, Ni, Cr, V, Cu, Mn, Fe and Zn that were less than the permitted daily exposures (PDE) and the limited concentration permitted in the EMEA guideline on the specification limits for residues of metal catalysts or metal reagents [1] . The metal residues can de adequately removed from the active pharmaceutical ingredients and the corresponding drugs. The trace metal residues will not affect human health and lead to the safety hazard by the intravenous injection. 关键词：ICP-AES platinum-based antitumor drug metal reagent residue safety

相关文献

参考文献（7）
引证文献（0）
耦合文献（13）

参考文献(7)

耦合文献(13)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Determination of Residues and Safety Analysis of Metal Impurities in Platinum-based Antitumor Drugs

参考文献(7)

耦合文献(13)

用户提示